The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 11, 2007, Pages 4165-4171

  El Ouaghlidi, Andrea ^a   Rehring, Erika ^a   Holst, Jens J ^b   Schweizer, Anja ^c   Foley, James ^c   Holmes, David ^c   Nauck, Michael A ^a,d  

^a Diabeteszentrum   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NOVARTIS PHARMA AG   (Switzerland)

^d DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; VILDAGLIPTIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; NEGATIVE FEEDBACK; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL;

EID: 35948941910     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1932     Document Type: Article

References (38)

1. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24
2. Holst JJ, Deacon CF 1998 Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
3. Deacon CF, Holst JJ 2002 Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem Biophys Res Commun 294:1-4
4. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ 2001 Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50:1588-1597
5. Deacon CF, Hughes TE, Holst JJ 1998 Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769
6. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ 2002 Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355-362
7. Hansen L, Hartmann B, Mineo H, Holst JJ 2004 Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 118:11-18
8. Åhren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
9. Åhren B, Gomis R, Standl E, Mills D, Schweizer A 2004 Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
10. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
11. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA 2005 Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675-688
12. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA 2006 Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612-4619
13. El-Ouaghlidi A, Rehring E, Schweizer A, Holmes D, Nauck MA 2003 The dipeptidyl peptidase IV inhibitor LAF237 does not accentuate reactive hypoglyaemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diabetes 52(Suppl 1):A118 (Abstract 507-P)
14. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Holmes D, Nauck MA 2004 Reduced increments in total glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in plasma after a single dose of the dipeptidyl peptidase-4 inhibitor LAF237 before an oral glucose load in healthy subjects. Diabetologia 47(Suppl 1):A (Abstract 786)
15. Krarup T, Madsbad S, Moody A, Regeur L, Faber O, Holst J, Sestoft L 1983 Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I diabetics. J Clin Endocrinol Metab 56:1306-1312
16. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539
17. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001 Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
18. Holst JJ 1982 Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207:381-388
19. Ghoos YE, Maes BD, Gaypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G 1993 Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 104:1640-1647
20. Braden B, Adams S, Duan LP, Orth KH, Maul FD, Lembcke B, Hör G, Caspary WF 1995 The [13C]acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology 108:1048-1055
21. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA 2003 Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725
22. Toft-Nielsen M, Madsbad S, Holst JJ 1998 Exaggerated secretion of glucagonlike peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41:1180-1186
23. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D 1984 Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328
24. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Frank BH, Galloway JA, Van Cauter E 1988 Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231-1239
25. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X 1999 Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
26. Olholm Larsen M, Rolin B, Ribel U, Wilken M, Deacon CF, Svendsen O, Gotfredsen CF, Carr RD 2003 Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced β-cell mass. Exp Diabetes Res 4:93-105
27. Åhren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P-A, Sandquist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D 2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
28. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ 2000 Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 278:E1010-E1018
29. Holst JJ, Deacon CF 2005 Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612-615
30. Nauck MA, El-Ouaghlidi A 2005 The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1 (for debate). Diabetologia 48:608-611
31. Dardik B, Valentin M, Schwartzkopf C, Gutierrez C, Stevens D, Russell ME, Edwin V, Hughes T 2003 NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant Cynomolgus monkeys. Diabetes 52(Suppl 1):A322 (Abstract 1292-P)
32. Åhren B, Pacini G, Foley JE, Schweizer A 2005 Improved meal-related betacell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28:1936-1940
33. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
34. Burcelin R, Da Costa A, Drucker D, Thorens B 2001 Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50:1720-1728
35. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD 2004 Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 287:E75-E81
36. Gribble FM, Tucker SJ, Seino S, Ashcroft FM 1998 Tissue specificity of sulfonylureas. Studies on cardiac and β-cell KATP channels. Diabetes 47:1412-1418
37. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD 2003 Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377
38. Hoffmann T, Iwanow K, Wolf R, Demuth H, Nauck M 2002 The important effect of meal stimulated incretin secretion on blood sugar regulation could not be improved by the DP IV-inhibitor P 32/98 in healthy subjects. Diabetologia 45(Suppl 2):A176 (Abstract 543)